Labcorp Holdings Inc. LH

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

Con 3 acciones de LH (USD 930,59) habrías recibido USD 8,64 en dividendos en los últimos 12 meses.

• Zacks Investment Research 30 sept

  DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?

  Danaher Corporation's Biotechnology segment drove growth with 4% reported sales increase to $1.92 billion in Q2 2026, bolstered by strong China demand and consumables sales. Despite regional headwinds in Western Europe and North America, DHR expects mid-single-digit core growth in 2026. The stock trades at a premium valuation of 24.92X forward P/E versus the industry average of 16.59X and carries a Zacks Rank #3 (Hold).

  

• Zacks Investment Research 29 sept

  Is This the Right Time to Add Labcorp Stock to Your Portfolio?

  Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.

  

• GlobeNewswire Inc. 28 sept

  GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

  GENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.

  

• GlobeNewswire Inc. 24 sept

  Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments

  The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.

  

• The Motley Fool 22 sept

  Why Labcorp Holdings Stock Dropped Today

  Labcorp Holdings stock fell 3.3% after the Centers for Medicare & Medicaid Services announced plans to reduce lab testing reimbursement rates by 15% starting next year, with potential additional cuts through 2029. Since CMS accounts for approximately 8% of Labcorp's revenue, a full 15% reduction would decrease annual revenue by 1.2%, with a worst-case scenario of 3.6% reduction if cuts continue through 2029. The stock's decline appears to have already priced in this worst-case scenario.